Document is current

Article History

Received: 15 January 2026

Revised: 30 March 2026

Accepted: 28 April 2026

First Online: 13 May 2026

Competing interests

: LR: has received research support from BMS, has served in advisory boards for Amgen, BMS, Roche, Johnson & Johnson, Sanofi, GSK, and Pfizer, and received honoraria from Amgen, BMS, Roche, Johnson & Johnson, Sanofi, GSK, Pfizer, and Takeda. MTK: consultant for and has served in advisory boards for: Amgen, Celgene, Novartis, BMS, J&J, Sanofi, GSK, Takeda, Pfizer, Oncopeptides, and Stemline. HA: has received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Takeda, and has received research support from Johnson & Johnson. CR: has served in advisory boards for BMS/Celgene, BeiGene, Roche, Johnson & Johnson, Sanofi, GSK, and Pfizer, and received honoraria from BMS/Celgene, Roche, Johnson & Johnson, Sanofi, Pfizer, and Stemline. IS: has served in advisory boards for: Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Sanofi, and received honoraria from Abbvie, Amgen, BMS, Gilead, GSK, Johnson & Johnson, Pfizer, Sanofi, Stemline, and Takeda. RT: has served in advisory boards for AbbVie, Amgen, BMS, Gilead, GSK, Johnson & Johnson, Oncopeptides, Sanofi, Stemline and Takeda, received research support from Johnson & Johnson, received travel grants from Amgen and Johnson & Johnson and received honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Pfizer and Stemline. VV: has received research support from Amgen, has served on advisory boards for Amgen, BMS/Celgene, Johnson & Johnson, Gilead/Kite, AstraZeneca, Abbvie and received honoraria from Johnson & Johnson, Gilead/Kite, Abbvie, AstraZeneca, Elli Lilly, and Roche. KW: has received research support from Abbvie, Amgen, BMS, Johnson & Johnson, GSK, and Sanofi, received honoraria from Abbvie, Adaptive Biotech, Amgen, Astra Zeneca, BeiGene, BMS, Johnson & Johnson, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, Takeda, has received consulting fees from Abbvie, Adaptive Biotech, Amgen, Astra Zeneca, BeiGene, BMS, CellCentric, Johnson & Johnson, GSK, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, Takeda WW: has received research support from Amgen, Astra-Zeneca, BMS/Celgene, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, and Takeda, has participated in steering and safety committees, advisory boards and given lectures for Amgen, Abbvie, Astra Zeneca, BeiGene, BMS/Celgene, Blueprint, CSL-Behring, Dayton, DSMM, EUSA Pharma, Gilead, GSK, IQVIA, Incyte, Johnson & Johnson, Kite, Merck, Myelom- and Lymphomselbsthilfe Österreich, MedMedia, Morphosys, Novartis, Onconovum, Pharma&, Pfizer, Roche, Sandoz, Sanofi, Stemline-Menarini, Takeda MSR: has received research funding from BMS, Johnson & Johnson, Sanofi, and Heidelberg Pharma, has received honoraria from BMS, Johnson & Johnson, AbbVie, Sanofi, Oncopeptides, has performed a consulting or advisory role for BMS, Amgen, GSK, Johnson & Johnson, Sanofi, Pfizer, AbbVie and has received travel funding from BMS, Amgen, Johnson & Johnson, Oncopeptides